EMA Authorised: Kisunla (donanemab) — Eli Lilly Nederland B.V.

View source ↗

Summary

EMA authorised Kisunla (donanemab) for Alzheimer's disease and cognitive dysfunction in the European Union. Eli Lilly Nederland B.V. is the marketing authorizat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Dysfunction

Drugs mentioned

• Kisunla (DONANEMAB-AZBT)

Snippet

Status: Authorised. Therapeutic area: Alzheimer Disease;Cognitive Dysfunction. MAH: Eli Lilly Nederland B.V.. Decision date: 26/02/2026